Marvin Slosman Purchases 21,000 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) CEO Marvin Slosman purchased 21,000 shares of InspireMD stock in a transaction on Tuesday, May 12th. The shares were acquired at an average cost of $1.20 per share, with a total value of $25,200.00. Following the completion of the transaction, the chief executive officer directly owned 3,556,658 shares in the company, valued at $4,267,989.60. The trade was a 0.59% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

InspireMD Trading Down 2.6%

NSPR opened at $1.14 on Friday. InspireMD, Inc. has a 12-month low of $1.02 and a 12-month high of $2.93. The firm has a market capitalization of $53.40 million, a PE ratio of -1.52 and a beta of 0.82. The firm has a 50 day moving average of $1.45 and a two-hundred day moving average of $1.71.

Institutional Investors Weigh In On InspireMD

A number of institutional investors have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. grew its stake in InspireMD by 70.6% in the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock valued at $9,413,000 after acquiring an additional 1,616,644 shares during the period. Nantahala Capital Management LLC grew its stake in InspireMD by 45.7% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock valued at $8,137,000 after acquiring an additional 1,058,467 shares during the period. Aberdeen Group plc grew its stake in InspireMD by 27.9% in the 4th quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock valued at $5,649,000 after acquiring an additional 692,247 shares during the period. Orbimed Advisors LLC grew its stake in InspireMD by 46.9% in the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock valued at $5,577,000 after acquiring an additional 1,000,000 shares during the period. Finally, Parkman Healthcare Partners LLC grew its stake in InspireMD by 97.6% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock valued at $5,882,000 after acquiring an additional 1,205,328 shares during the period. Institutional investors and hedge funds own 44.78% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on NSPR shares. Lake Street Capital set a $4.00 price target on shares of InspireMD in a research report on Monday, May 4th. Maxim Group started coverage on shares of InspireMD in a research report on Monday, February 2nd. They set a “buy” rating and a $6.00 price target for the company. Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $4.50.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.